DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for ETtech Unwrapped Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE WED, JUN 26, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly and other drugmakers showed off encouraging data on weight loss and diabetes drugs last week.  Companies shared results at the American Diabetes Association's annual meeting in Orlando, Florida, the world's biggest scientific conference focused on diabetes research, prevention and care.  The drug developments come amid growing investor interest in the treatment of metabolic diseases and specifically, a buzzy class of medications called GLP-1s But drugmakers presented treatments that use different approaches than traditional GLP-1s such as Novo Nordisk's popular weight loss injection Wegovy and diabetes counterpart Ozempic. The two medications mimic a hormone produced in the gut to suppress a person's appetite.  Companies are also pivoting away from focusing on weigh